# [New Market Research] What's holding life science R&D back?

Canonical: https://brew.new/browse/templates/email/pt1_k97j5qf4zqe62mnahb6hq6ad6d8e5fzs

Brand: patsnap.com
Category: newsletter

![Preview of [New Market Research] What's holding life science R&D back?](https://cdn.brew.new/email-preview-ff8871d0d25e66f2-tracking_r57g34sk317jfp0pfavhamy0r18dv6e2-1789009720431.png)

## Email content

R&D Report Header

Hi there,

Pipeline attrition is expected in life sciences. What isn't acceptable is finding out why a program failed after you've already spent two years on it.

We surveyed 200+ R&D leaders earlier this year. Across pharma, biotech, and medical devices, the same problem kept surfacing: IP and competitive intelligence showing up too late to change anything. 38% of organizations estimate the cost of a late-stage kill at $1M to $5M. Per project!

The 2026 R&D Benchmark Report looks at where those decisions go wrong and how access to the right intelligence earlier can reduce waste.

Get the report

We hope you find it useful.

Sincerely,

The Patsnap Team

Patsnap, 26 Wellington St E, Toronto, ON M5E 1W9, Canada

Unsubscribe

Manage preferences

[Open and remix this design](https://brew.new/browse/templates/email/pt1_k97j5qf4zqe62mnahb6hq6ad6d8e5fzs)

[Browse email designs](https://brew.new/browse/templates)